Jan. 30, 2023 – Health Imaging reports on a new case study published indicating that radioisotope supply issues are delaying prostate cancer treatments using 177Lu-PSMA-617, commonly known as Pluvicto.
The health care news source writes:
Following its [2022 FDA] approval, clinicians at the Dana Farber Cancer Institute report that 146 patients were referred to them to undergo therapy using 177Lu-PSMA-617 between May and October of 2022.
Of those patients, 127 were approved for the therapy, and by the end of October 2022, less than half (41%) of the approved patients had completed one cycle of 177Lu-PSMA-617.
…During the institute’s implementation, patients’ treatments were delayed by three months due to low supply of 177Lu-PSMA-617 and some (5%) patients even died while awaiting treatment.
The clinical implementation case study is published in the Journal of Nuclear Medicine: Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges.